Replies to post #3048 on GTC Biotherapeutics (fka GTCB)

[DB9]

I agree.
I thought, Dr. Geoffrey Cox said:

Let me take a few moments to make some additional comments.


Turning first to our malaria vaccine program, we have entered into further discussions with the National Institute of Allergy and Infectious Diseases for the funding of this product. We have supplied some further material to the NIAID for evaluation for further development and we are seeking to restore funding of this program. We believe there is value to this product in the treatment and prevention of malaria, which remains one of the major causes of death in children under five years old in developing countries.